Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer

Shinya Oki; Kenbun Sone; Katsutoshi Oda; Ryuji Hamamoto; Masako Ikemura; Daichi Maeda; Makoto Takeuchi; Michihiro Tanikawa; Mayuyo Mori-Uchino; Kazunori Nagasaka; Aki Miyasaka; Tomoko Kashiyama; Yuji Ikeda; Takahide Arimoto; Hiroyuki Kuramoto; Osamu Wada-Hiraike; Kei Kawana; Masashi Fukayama; Yutaka Osuga; Tomoyuki Fujii

doi:10.18632/oncotarget.16316

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer

Shinya Oki, Kenbun Sone _, Katsutoshi Oda, Ryuji Hamamoto, Masako Ikemura, Daichi Maeda, Makoto Takeuchi, Michihiro Tanikawa, Mayuyo Mori-Uchino, Kazunori Nagasaka, Aki Miyasaka, Tomoko Kashiyama, Yuji Ikeda, Takahide Arimoto, Hiroyuki Kuramoto, Osamu Wada-Hiraike, Kei Kawana, Masashi Fukayama, Yutaka Osuga and Tomoyuki Fujii

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:40402-40411. https://doi.org/10.18632/oncotarget.16316

Metrics: PDF 2103 views | HTML 3854 views | ?

Abstract

Shinya Oki1, Kenbun Sone1, Katsutoshi Oda1, Ryuji Hamamoto2, Masako Ikemura3, Daichi Maeda4, Makoto Takeuchi1, Michihiro Tanikawa1, Mayuyo Mori-Uchino1, Kazunori Nagasaka1, Aki Miyasaka1, Tomoko Kashiyama1, Yuji Ikeda1, Takahide Arimoto1, Hiroyuki Kuramoto5, Osamu Wada-Hiraike1, Kei Kawana1, Masashi Fukayama3, Yutaka Osuga1 and Tomoyuki Fujii1

1Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan

2Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan

3Department of Pathology, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan

4Department of Pathology, Faculty of Medicine, Akita University, Akita 010-8543, Japan

5Center for Female Preventive Medicine, Kanagawa Health Service Association, Naka-ku, Yokohama, Kanagawa 231-0021, Japan

Correspondence to:

Kenbun Sone, email: [email protected]

Keywords: histone methyltransferase, EZH2, endometrial cancer, GSK126, H3K27 trimethylation

Received: August 15, 2016 Accepted: February 17, 2017 Published: March 17, 2017

ABSTRACT

The histone methyltransferase EZH2, a key epigenetic modifier, is known to be associated with human tumorigenesis. However, the physiological importance of EZH2 and its clinical relevance in endometrial cancer remain unclear. Hence, in the present study, we investigated the expression and function of EZH2 in endometrial cancer. In a quantitative real-time PCR analysis of 11 endometrial cancer cell lines and 52 clinical endometrial cancer specimens, EZH2 was significantly overexpressed in cancer cells and tissues compared to that in corresponding normal control cells and tissues. Kaplan-Meier survival analysis using data of the TCGA RNA-seq database and tissue microarrays (TMAs) indicated that EZH2 overexpression is associated with endometrial cancer prognosis. In addition, knockdown of EZH2 using specific siRNAs resulted in growth suppression and apoptosis induction of endometrial cancer cells, accompanied by attenuation of H3K27 trimethylation. Consistent with these results, treatment with GSK126, a specific EZH2 inhibitor, suppressed endometrial cancer cell growth and decreased the number of cancer cell colonies. Furthermore, GSK126 showed additive effects with doxorubicin or cisplatin, which are conventional drugs for treatment of endometrial cancer. Further studies should explore the therapeutic potential of inhibiting EZH2 in patients with endometrial cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16316

Publication Alerts

Research Papers:

Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer

Abstract